Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
479
Employees479
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
479
Employees479

REPL Key Statistics

Market cap
649.84M
Market cap649.84M
Price-Earnings ratio
-2.62
Price-Earnings ratio-2.62
Dividend yield
Dividend yield
Average volume
1.55M
Average volume1.55M
High today
$9.00
High today$9.00
Low today
$8.15
Low today$8.15
Open price
$8.41
Open price$8.41
Volume
1.09M
Volume1.09M
52 Week high
$17.00
52 Week high$17.00
52 Week low
$4.92
52 Week low$4.92

REPL News

TipRanks 5d
Replimune Group’s Internal Control Weaknesses Threaten Financial Stability and Investor Confidence

Replimune Group (REPL) has disclosed a new risk, in the Accounting & Financial Operations category. Confident Investing Starts Here: Easily unpack a company's...

TipRanks 7d
Replimune reports Q4 EPS ($3.07), consensus (69c)

“As we near our PDUFA date, our commercial organization is now fully hired and ready to execute our first launch in advanced melanoma,” said Sushil Patel, Ph.D....

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.